QBIO - Q BioMed expands Strontium89 to Chinese market with $500K order

Q BioMed (OTCQB:QBIO) said it received $500K order for its Strontium Chloride USP Injections under a supply contract between its Canadian distribution partner isoSolutions Marketing and Management, and Chinese company Chengdu Syncor Pharmaceutical. The company said Strontium89 is an FDA-approved non-opioid radiopharmaceutical to help relieve bone pain that may occur with certain types of cancer. QBIO expects to start shipping doses in April and will continue through 2023. The company said the agreement is the first of what is expected to be a high-growth named patient opportunity to supply Strontium89 in the Chinese market. The company noted that the Chinese market is currently demanding 12K doses a year from two local government run manufacturers.

For further details see:

Q BioMed expands Strontium89 to Chinese market with $500K order